GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
April 27, 2022 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on...
GBT Announces New Employment Inducement Grants
April 07, 2022 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2022, the compensation committee of GBT’s board...
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
March 24, 2022 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the...
GBT Announces New Employment Inducement Grants
March 10, 2022 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2022, the compensation committee of GBT’s board...
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
March 03, 2022 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced it is...
GBT Announces Participation in Upcoming Investor Conferences
February 28, 2022 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following...
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $56.1 million in the fourth quarter and $194.7 million for full year 2021, a 57% increase year over year Executed on key growth opportunities highlighted...
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
February 16, 2022 16:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial...
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
February 16, 2022 06:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the European Commission (EC) has granted Marketing Authorization...
GBT Announces New Employment Inducement Grants
February 03, 2022 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2022, the compensation committee of GBT’s board...